Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 2/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.48 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28475012 | 0.87 | VNN1 (0.56) | EPHX1TRPM8MAPK14CETPVNN1 | |
| SCHEMBL761677 | 0.85 | MAPK14 (0.54) | TRPM8MAPK14CETPVNN1CHRM2 | |
| SCHEMBL30487710 | 0.84 | CHRM2 (0.52) | EPHX1TRPM8MAPK14CETPAMPD2 | |
| SCHEMBL21981021 | 0.84 | AOC2 (0.51) | MAPK14VNN1CNR1ROCK2ROCK1 | |
| SCHEMBL5724443 | 0.84 | CHRM2 (0.52) | EPHX1TRPM8MAPK14CETPAMPD2 | |
| Hydrochloric Acid SCHEMBL2525556 | 0.84 | MAPK14 (0.53) | TRPM8MAPK14CETPVNN1CHRM2 | |
| SCHEMBL11546048 | 0.84 | CHRM2 (0.51) | EPHX1TRPM8MAPK14CETPVNN1 | |
| SCHEMBL1792094 | 0.84 | CNR1 (0.50) | EPHX1TRPM8MAPK14RIPK1CETP | |
| SCHEMBL934552 | 0.83 | CHRM2 (0.51) | EPHX1TRPM8MAPK14CETPAMPD2 | |
| SCHEMBL31481109 | 0.82 | MEP1B (0.52) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3383873-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | claimed |
| WO-2017093299-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | claimed |
| EP-3092235-A2 | NOVEL INHIBITORS OF GLUTAMINASE | Rhizen Pharmaceuticals S.A. (CH) | 2016-11-16 | — | — | EP | claimed |
| CN-105960405-A | glutaminase inhibitors | 理森制药股份公司 | 2016-09-21 | — | — | CN | claimed |
| WO-2015101958-A2 | NOVEL INHIBITORS OF GLUTAMINASE | RHIZEN PHARMACEUTICALS SA (CH) | 2015-07-09 | — | — | WO | claimed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-118317773-A | Pharmaceutical composition for treating cancer | 卡尼姆生物有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-116283990-B | Application of substituted pyrrolidone compound as tumor necrosis factor inhibitor | 沈阳药科大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-116789670-A | Selective CSF1R inhibitor and application thereof | 中国科学院合肥物质科学研究院 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023173480-A1 | SELECTIVE CSF1R INHIBITOR AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2023-09-21 | — | — | WO | disclosed |
| CN-116283990-A | Application of substituted pyrrolidone compound as tumor necrosis factor inhibitor | 沈阳药科大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-116234810-A | Cell apoptosis inhibitor and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2023-06-06 | — | — | CN | disclosed |
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8846698-B2 | Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors | PFIZER LIMITED (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| WO-2004060281-A2 | 2-ARYL THIAZOLE DERIVATIVES AS KCNQ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-22 | — | — | WO | disclosed |
| EP-1434765-A1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | NOVO NORDISK A/S (DK) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003024929-A1 | SUBSTITUTED PIPERIDINES WITH SELECTIVE BINDING TO HISTAMINE H3-RECEPTOR | NOVO NORDISK A/S (DK) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364415-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | EPHX1 4360/4885TRPM8 1175/4885MAPK14 239/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | EPHX1 4360/4885TRPM8 1175/4885MAPK14 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.